Evidence map›Paper›PMID 29369166›Full record

Trial reportAIDS (London, England)2018

Novel mediators of statin effects on plaque in HIV: a proteomics approach.

Chris deFilippi, Janet Lo, Robert Christenson, Ida Grundberg, Lauren Stone, Markella V Zanni, Hang Lee, Steven K Grinspoon

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chris deFilippiInova Heart and Vascular Institute, Falls Church, Virginia.
Janet LoProgram in Nutritional Metabolism, MGH and Harvard Medical School, Boston.
Robert ChristensonDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ida GrundbergOlink Proteomics, Watertown.
Lauren StoneProgram in Nutritional Metabolism, MGH and Harvard Medical School, Boston.
Markella V ZanniProgram in Nutritional Metabolism, MGH and Harvard Medical School, Boston.
Hang LeeMGH Biostatistics Center, MGH and Harvard Medical School, Boston, Massachusetts.
Steven K GrinspoonProgram in Nutritional Metabolism, MGH and Harvard Medical School, Boston.
Harvard University · USAlaska Heart and Vascular Institute · USUniversity of Maryland, Baltimore · US

Funding

ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

objectiveHIV patients have increased atherosclerotic coronary vascular disease (ASCVD), thought to be mediated through inflammatory mechanisms. We hypothesized that among asymptomatic HIV-infected patients with subclinical coronary plaque, statin therapy would modulate unique inflammatory and cardiovascular proteins in relation to change in subclinical coronary plaque volume. We tested this hypothesis using a novel proteomics approach.

designForty HIV-infected participants were randomized to atorvastatin (40 mg/day) versus placebo, and underwent computed tomography coronary angiography to quantify plaque volume at baseline and 1 year.

methodsWe used Olink Cardiovascular III and Cardiometabolic panels based on dual antibody epitope recognition with linked DNA amplification to compare change over time in 184 proteins in treatment versus placebo and in relation to change in coronary plaque volume.

resultsSix proteins (TFPI, CCL24, NT-Pro BNP, MBL2, LTBR, PCOLCE) changed significantly in the atorvastatin versus placebo group, many in innate immune and other novel inflammatory pathways. Twenty-six proteins changed significantly in relationship to total coronary plaque volume over 1 year. Notably, many of these proteins changed only weakly in relationship to change in low-density lipoprotein (LDL). Overlapping these two broad discovery approaches, proteins involved in myocardial fibrosis/collagen formation and monocyte chemoattraction changed with statin treatment, in relationship to plaque volume, but not LDL.

conclusionThis proof-of-concept study employing a proteomic discovery platform offers insight into statin effects on novel immune pathways relevant to ASCVD progression in HIV. Novel biomarker discovery may enhance precision medicine strategies to estimate the efficacy of targeted therapies to reduce ASCVD progression and events in HIV.

Indexed as

AdultAgedAnticholesteremic AgentsAtorvastatinCoronary AngiographyCoronary Artery DiseaseDouble-Blind MethodFemaleHIV InfectionsHumansMaleMiddle AgedPlacebosProteomeProteomicsTomography, X-Ray ComputedAnticholesteremic AgentsAtorvastatinPlacebosProteome

Identifiers

PMID29369166
PMCPMC5869115
OpenAlexW2792943474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.